Free Trial
NASDAQ:BRKR

Bruker Q2 2025 Earnings Report

Bruker logo
$42.12 -0.24 (-0.57%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$42.12 0.00 (0.00%)
As of 07/9/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bruker EPS Results

Actual EPS
N/A
Consensus EPS
$0.43
Beat/Miss
N/A
One Year Ago EPS
N/A

Bruker Revenue Results

Actual Revenue
N/A
Expected Revenue
$811.17 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bruker Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Bruker Earnings Headlines

1 Healthcare Stock for Long-Term Investors and 2 to Question
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Bruker Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bruker? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bruker and other key companies, straight to your email.

About Bruker

Bruker (NASDAQ:BRKR) (NASDAQ:BRKR) is a leading provider of scientific instruments and analytical solutions used in molecular and materials research, as well as in industrial applications and molecular diagnostics. Founded in 1960 in Germany by Dr. Günther Laukien, Bruker has grown through innovation and strategic acquisitions to offer a broad portfolio of technologies, including nuclear magnetic resonance (NMR), mass spectrometry, X-ray diffraction, electron microscopy, and infrared and Raman spectroscopy systems.

The company’s operations are organized into several business segments, each focused on distinct markets. Bruker BioSpin develops high-field NMR spectrometers and preclinical imaging systems for pharmaceutical, academic and biotechnology research. Bruker Daltonics delivers mass spectrometry and chromatography solutions for proteomics, metabolomics, microbiology, and environmental testing. Bruker’s X-ray and Electron Microscopy division produces X-ray diffraction, X-ray fluorescence and electron microscopy instruments critical to materials science, semiconductor research and quality control. Additionally, the company’s molecular diagnostics portfolio includes MALDI Biotyper systems, which support rapid microbial identification in clinical and industrial laboratories.

Headquartered in Billerica, Massachusetts, Bruker maintains a global footprint with research and manufacturing facilities in North America, Europe, and Asia. The company serves customers in more than 90 countries through a combination of direct sales and an extensive network of distributors. Bruker invests heavily in research and development, collaborating with universities, research institutes and industrial partners to drive innovation in areas such as structural biology, nanotechnology and advanced materials characterization.

Under the leadership of Chairman, President and Chief Executive Officer Dr. Frank H. Laukien, Bruker continues to emphasize technological advancement and operational excellence. The management team’s focus on scientific breakthroughs, along with a commitment to quality and customer support, has positioned the company as a trusted partner for researchers and industries seeking precision analytical tools. As a publicly traded company on the NASDAQ, Bruker leverages its expertise in instrumentation and software to address emerging challenges in healthcare, energy, environmental science and beyond.

View Bruker Profile

More Earnings Resources from MarketBeat